相关实验视频
Updated: Jan 10, 2026
09:03
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
19.8K
CYP2C29单氧化酶促进了CDAA-HFD诱导的肝纤维化
Nan Jing1, Matthew L Edin2, Fred B Lih2
1Department of Nutrition, University of California, Davis, CA, USA.
Free radical biology & medicine
|November 20, 2025
概括
细胞染色体P450 (CYP) 途径,特别是CYP2C29,在代谢功能障碍相关的脂肪肝炎 (MASH) 中促进肝纤维化. 在小鼠模型中,抑制这种途径可以减少纤维化和炎症.
科学领域:
- 生物化学 生物化学
- 肝病学 肝病学是一种肝病学.
- 脂质代谢 脂质代谢是什么
背景情况:
- 细胞染色体P450 (CYP) 单氧化酶将多不和脂肪酸代谢成生物活性环氧脂肪酸 (EpFA) 和脂肪酸二醇.
- 这些脂质介质调节炎症,但它们在代谢功能障碍相关的脂肪肝炎 (MASH) 和肝纤维化中的作用尚不清楚.
- 在这些脂肪酸的肝脏代谢中,CYP2C和CYP2J异型占主导地位.
研究的目的:
- 为了研究CYP2C29的作用,一个主要的小鼠肝CYP异型,在饮食诱导的肝纤维化发展.
- 确定CYP2C29活性是否影响MASH中与纤维化,炎症和血管生成相关的基因的表达.
主要方法:
- 使用胆缺乏,L-氨基酸定义,高脂肪饮食 (CDAA-HFD) 的小鼠模型诱导肝纤维化.
- 产生了CYP2C29淘汰赛 (KO) 的小鼠,并将它们与野生类型 (WT) 的 littermates进行了比较.
- 分析了肝脂度,并进行了转录基因分析以评估基因表达.
主要成果:
- 与WT小鼠相比,CYP2C29 KO小鼠的CYP衍生的EPFA和脂肪酸二醇的肝脏水平降低.
- 在CDAA-HFD模型中,CYP2C29缺乏减轻了肝纤维化的发展.
- 破坏Cyp2c29抑制了亲纤维基因,亲炎症基因和亲血管基因的肝脏表达.
结论:
- 在MASH中,CYP单氧化酶通路,特别是CYP2C29在促进肝纤维化方面发挥着重要作用.
- 在MASH期间,CYP2C29的活动有助于肝脏的亲纤维,亲炎症和亲血管环境.
- 向CYP途径可能提供一种治疗策略,用于管理MASH中的肝纤维化.
相关概念视频
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
01:19Allosteric Proteins-ATCase
6.4K
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.4K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
01:17Drug Metabolism: Phase I Reactions
4.5K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.5K